Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

IgG4 Related Disease Clinical Trial

Official title:

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04918147
• Other study ID #: DAIT AIG01
• Secondary ID: UM1AI144298NIAID
• Status: Terminated
• Phase: Phase 2
• Start date: October 13, 2021
• Est. completion date: January 4, 2024

Study information

• Verified date: January 2024
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a two-part multi-center clinical trial in participants with active IgG4-RD. Part 1 (Cohort 1a and Cohort 1B) is an open-label, dose escalation phase to determine the safety of elotuzumab for investigation in IgG4-RD. Part 2 (Cohort 2) is a randomized, placebo-controlled, double-blinded (masked) trial phase to compare the effects of elotuzumab and prednisone to elotuzumab placebo and prednisone in participants with IgG4 RD. Approximately 75 participants with active IgG4-RD will be enrolled in the overall program, 12 in Part 1 and 63 in Part 2. Randomization in Part 2: 2 to 1, with approximately forty-two participants randomized to elotuzumab plus prednisone taper, and twenty-one participants randomized to placebo for elotuzumab plus prednisone taper. The total duration of participation for each participant in this trial will be 48 weeks (11 months).

Description:

Immunoglobulin G4-Related Disease (IgG4-RD) is a chronic fibro-inflammatory condition that can affect virtually every organ system, including the pancreas, biliary tract, salivary and lacrimal glands, orbits, lungs, kidneys, meninges, pituitary gland, prostate and thyroid. It may also involve the retroperitoneum. This multi-organ immune-mediated condition, once regarded as a group of isolated, single-organ diseases, is now recognized to be an overarching, single-disease entity linked by common histopathological and immunohistochemical features. IgG4-RD tends to afflict middle-aged to elderly individuals. Although IgG4-RD can affect a single organ at presentation, it is not uncommon for participants to present with or develop multi-organ disease. As the disease progresses, additional organs develop lesions and the cellular inflammation characterizing early disease moves toward a more fibrotic stage, causing major tissue damage, dysfunction and ultimately organ failure. It is unclear whether IgG4 itself is involved in the pathogenesis of the disease. The goals of IgG4-RD treatment are to reduce inflammation and organ swelling and to prevent or reverse tissue fibrosis. No approved therapy exists for IgG4-RD. This study will enroll adult participants who meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria for IgG4-RD, and who have active IgG4-RD with disease manifestations in at least two organ systems. Primary study objectives: - To determine the safety and tolerability of the addition of elotuzumab to prednisone in participants with IgG4-RD, and - To compare the effect of the addition of elotuzumab versus placebo to prednisone on the IgG4-RD Responder Index (IgG4-RD RI), a measure of IgG4-RD disease activity.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: January 4, 2024
• Est. primary completion date: January 4, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

Individuals who meet all of the following criteria are eligible for enrollment as study

participants:

1. Participant must be able to understand and provide informed consent and be willing to comply with study procedures and follow up.

2. Are at least 18 years of age and not older than 70 years of age at screening.

3. Meet the ACR/EULAR Classification Criteria for IgG4-RD [30, 31].

4. Have active disease based at screening on an IgG4-RD RI =4, with disease manifestations in at least two organ systems.

5. May have newly-diagnosed or relapsing disease at screening. Relapsing disease is defined as IgG4-RD that has previously been in remission but is now active again.

6. May be on treatment or off treatment for IgG4-RD at the time of screening. If on treatment, must be willing to discontinue those other treatments before the baseline visit.

7. No history of severe allergic reactions to monoclonal antibodies.

8. Female participants of childbearing potential must have a negative pregnancy test upon study entry.

9. Female participants of childbearing potential and male participants with a partner of childbearing potential must agree to consistently and correctly use FDA approved highly effective methods of birth control for the entire duration of the study and 6 months after last elotuzumab infusion.

10. Immunization with one of the FDA authorized or licensed SARS-CoV-2 vaccines as per CDC recommendations at the time of informed consent is required for study entry. Vaccinations must have been completed at least 2 weeks prior to start of study therapy. Exclusion Criteria: Individuals who meet any of these criteria are not eligible for enrollment as study

participants:

1. Presence of a condition other than IgG4-RD that (e.g., asthma) is likely to require systemic Glucocorticoids (GC) for disease control during the period of the trial.

2. Malignancy within 5 years (except successfully treated in situ cervical cancer, resected squamous cell or basal cell carcinoma of the skin.)

3. The following lab values as indicators of hepatic dysfunction:

1. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than three times the upper limit of normal (ULN)

2. Total bilirubin > two times the ULN unless caused by Gilbert's disease. Gilbert's disease with total bilirubin > three times ULN.

3. Serum albumin < 2.5 gm/dL.

4. Evidence of another uncontrolled condition which, in the judgment of the investigator, could interfere with participation in the trial according to the protocol.

5. Active infection requiring hospitalization or treatment with systemic antimicrobial agents within the 30 days prior to treatment allocation/randomization.

6. Prior use of rituximab or other B cell depleting agents within 9 months of enrollment unless B cells have been demonstrated to have repopulated.

7. Use of any investigational agent or biologic and non-biologic DMARDs within 5 half-lives of the agent (or 6 months if the half-life is unknown) prior to enrollment.

8. Any of the following laboratory tests at the Screening Visit:

1. White blood cell count (WBC) < 3.0 x 103/µL.

2. Absolute neutrophil count (ANC) < 1.5 x 103/µL.

3. Hemoglobin < 10 g/dL.

4. Platelet count < 75 x 109/L.

5. Estimated glomerular filtration rate (eGFR) = 45 ml/minute/1.73 m2.

9. The use of supplemental oxygen at baseline.

10. At or within 90 days of screening: Positive Interferon-Gamma Release Assay (IGRA). Indeterminate IGRAs must be repeated (with same or other IGRA per local policy) and shown to be negative. Alternatively, if the assay remains indeterminant, a participant must have a negative PPD. Finally, if the participant has had the Bacille Calmette-Guerin (BCG) vaccine or has some other condition complicating the interpretation of TB testing, consultation with infectious disease specialist must be obtained before receipt of the first investigational infusion. a. Participants diagnosed with latent TB are eligible but must have received appropriate prophylaxis for 30 days before their first investigational infusion.

11. Medical history or serologic evidence at Screening of chronic infections including:

1. Human immunodeficiency virus infection.

2. Hepatitis B as indicated by surface antigen or hepatitis B core antibody positivity

3. Hepatitis C as indicated by anti-hepatitis C antibody positivity; if a participant is Hepatitis C antibody positive, they will be eligible to participate in the study if he/she is negative for viral load at Screening.

12. Live vaccines within 8 weeks of initiating study therapy.

13. Participant is pregnant or breastfeeding, or planning a pregnancy while enrolled in the study.

14. Substance use disorder, including the recurrent use of alcohol and/or drugs within the past year associated with clinically significant impairment associated with failure to meet major responsibilities at work, school, or home.

15. IgG4-RD that is dominated primarily by advanced fibrotic lesions. Specifically, participants whose disease manifestations consist only of

1. retroperitoneal fibrosis,

2. fibrosing mediatinitis,

3. sclerosing mesenteritis, or

4. Riedel's thyroiditis. Participants with these disease manifestations can be included, however, only if they have disease in 2 organ systems that is not of an advanced fibrotic nature and otherwise meet the Inclusion and Exclusion Criteria.

16. Evidence a SARS-CoV-2 (COVID-19) infection started within the 30 days prior to treatment allocation/randomization. Participants diagnosed with SARS-CoV-2 (COVID-19) infection more than 30 days prior to treatment allocation/randomization must have symptoms resolved and be deemed fit to participate in the trial.

Related Conditions & MeSH terms

• IgG4 Related Disease
• IgG4-RD

Intervention

Drug:
• elotuzumab
Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
• placebo for elotuzumab
The placebo for elotuzumab is 0.9% sterile normal saline for injection.
• methylprednisolone
Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
• diphenhydramine
Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
• acetaminophen
Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
• famotidine
Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
• prednisone
Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).

Locations

Country	Name	City	State
United States	Emory Healthcare	Atlanta	Georgia
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Mayo Clinic: Pulmonary and Critical Care Medicine	Rochester	Minnesota

Sponsors (4)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence, Bristol-Myers Squibb, Rho Federal Systems Division, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, Chari ST, Della-Torre E, Frulloni L, Goto H, Hart PA, Kamisawa T, Kawa S, Kawano M, Kim MH, Kodama Y, Kubota K, Lerch MM, Lohr M, Masaki Y, Matsui S, Mimori T, Nakamura S, Nakazawa T, Ohara H, Okazaki K, Ryu JH, Saeki T, Schleinitz N, Shimatsu A, Shimosegawa T, Takahashi H, Takahira M, Tanaka A, Topazian M, Umehara H, Webster GJ, Witzig TE, Yamamoto M, Zhang W, Chiba T, Stone JH; Second International Symposium on IgG4-Related Disease. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol. 2015 Jul;67(7):1688-99. doi: 10.1002/art.39132. No abstract available. — View Citation

Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Schleinitz N, Takahashi N, Umehara H, Zen Y, Stone JH; Members of the ACR/EULAR IgG4-RD Classification Criteria Working Group. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020 Jan;79(1):77-87. doi: 10.1136/annrheumdis-2019-216561. Epub 2019 Dec 3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Participants in Cohort 1a Who Experience at Least One Grade 3 or Higher Adverse Event	Safety measure. Evaluation of the severity of adverse events. Reference: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.	Up to Week 24 post treatment initiation
Primary	Proportion of Participants in Cohort 1b Who Experience at Least One Grade 3 or Higher Adverse Event	Safety measure. Evaluation of the severity of adverse events. Reference: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.	Up to Week 48 post treatment initiation
Primary	Participants in Cohort 2: Percent Change in Immunoglobulin G4-Related Disease Responder Index (IgG4-RD RI) Score	Efficacy measure. The IgG4-RD RI is used to assess disease response to treatments in IgG4-RD clinical trials.	Baseline (Day 0, prior to treatment initiation), Week 48
Secondary	Proportion of Participants by Cohort Group who Experience at Least One Grade 2 or Higher Adverse Event	Safety measure. Evaluation of the severity of adverse events. Reference: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.	Up to Week 48 post treatment initiation
Secondary	Proportion of Participants by Cohort Group with a Grade 3 or Higher Infection	Safety measure. Evaluation of the severity of infectious disease(s) adverse events. Reference: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.	Up to Week 48 post treatment initiation
Secondary	Proportion of Participants by Cohort Group who Experience a Malignancy	Safety measure. Evaluation of the severity of infectious disease(s) adverse events. Reference: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.	Up to Week 48 post treatment initiation
Secondary	Proportion of Participants by Cohort Group who Experience a Hepatotoxicity	Safety measure. Defined as an increase in the serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) to elevations three times the upper limit of normal (ULN).	Up to Week 48 post treatment initiation
Secondary	Proportion of Participants by Cohort Group who Experience a Serious Adverse Event	Safety measure defined as an adverse event or suspected adverse reaction that, in the view of either the investigator or sponsor results in any of the following outcomes (21 CFR 312.32(a)): Death; A life-threatening event; Inpatient hospitalization or prolongation of existing hospitalization; Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; Congenital anomaly or birth defect; Important medical events that may not result in death, be life threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above	Up to Week 48 post treatment initiation
Secondary	Proportion of Participants by Cohort Group who Experience Infusion Reactions	Safety measure defined as any adverse reaction within 24 hours of infusion which are Grade 2 or higher events and at least possibly related to study drug.	Up to 24 hours post treatment infusion
Secondary	Proportion of Participants in Cohort 2 who Experience at Least One Grade 3 or Higher Adverse Event	Safety measure. Evaluation of the severity of adverse events. Reference: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.	Up to Week 48 post treatment initiation
Secondary	Proportion of Participants in Cohort 2 in Complete Remission at Week 48	Efficacy measure, defined as: An IgG4-RD Responder Index (IgG4-RD RI) score of 0,; A glucocorticoid dose of 0 mg/day, and; No disease flare since beginning treatment.	Week 48 post treatment initiation
Secondary	Proportion of Participants by Cohort Group who Achieve =50 Percent (%) Improvement in IgG4-RD Responder Index (IgG4-RD RI) Score at Week 48	Efficacy measure. The IgG4-RD RI is used to assess disease response to treatments in IgG4-RD clinical trials. The IgG4-RD Responder Index Total Activity Score ranges from 0 to a maximum of 162. Higher scores represent greater (i.e. worse) disease activity.	Week 48 post treatment initiation
Secondary	Proportion of Participants by Cohort Group who Achieve =75 Percent (%) Improvement in IgG4-RD Responder Index (IgG4-RD RI) Score at Week 48	Efficacy measure. The IgG4-RD RI is used to assess disease response to treatments in IgG4-RD clinical trials. The IgG4-RD Responder Index Total Activity Score ranges from 0 to a maximum of 162. Higher scores represent greater (i.e. worse) disease activity.	Week 48 post treatment initiation
Secondary	Number of Immunoglobulin G4-Related Disease (IgG4-RD) Flares by Cohort Group by Week 48	Efficacy measure, defined as a recurrence of disease activity such that additional immunosuppressive therapy beyond the trial protocol is indicated.	Up to Week 48 post treatment initiation
Secondary	Change from Baseline in Physician Global Assessment (PhGA)-By Cohort Group	Efficacy measure.	Baseline through Week 48
Secondary	Change from Baseline in Patient Global Assessment (PGA)-By Cohort Group	Efficacy measure.	Baseline through Week 48
Secondary	Proportion of Participants by Cohort Group with Disease-Related Damage at Week 24	Efficacy measure. Disease-related damage, as measured by the damage section of the IgG4-RD Responder Index (IgG4-RD RI). The IgG4-RD RI is used to assess disease response to treatments in IgG4-RD clinical trials.	Week 48 post treatment initiation

External Links

•   Autoimmunity Centers of Excellence (ACE)
•   Division of Allergy, Immunology, and Transplantation (DAIT)
•   National Institute of Allergy and Infectious Diseases (NIAID)